Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
You may also be interested in...
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.
Investors will be eager to hear updates on Merck & Co.'s Keytruda market share versus other PD-1/L1 competitors in lung cancer, as well as other indications; Merck KGaA followers are watching for what sort of start its Pfizer Inc.-partnered checkpoint inhibitor Bavencio and the new multiple sclerosis drug Mavenclad have got off to.
Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.